Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion type Assertion NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_head.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion description "[ Combined pharmacogenetic testing for CYP2D6 and CYP2C19 identifies patients with low risk for side effects in amitriptyline therapy and could possibly be used to individualize antidepressive regimens and reduce treatment cost. Identification of genotypes associated with slightly reduced intermediate metabolism may be more important than currently anticipated. It could also be the key to demonstrating cost-effectiveness for CYP2D6 genotyping in critical dose drugs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_provenance.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion evidence source_evidence_literature NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_provenance.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion SIO_000772 15590749 NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_provenance.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion wasDerivedFrom gad-20130706 NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_provenance.
- NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_assertion wasGeneratedBy ECO_0000203 NP45800.RAEZoeYIeiv2MBrolNG3arZv6Eh2DyB-2OF9rFiJR1RBQ130_provenance.